TRELSTAR Drug Patent Profile

When do Trelstar patents expire, and when can generic versions of Trelstar launch?

Trelstar is a drug marketed by Verity and is included in three NDAs. There is one patent protecting this drug.

This drug has forty-seven patent family members in thirty-two countries.

The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the triptorelin pamoate profile page.

DrugPatentWatch^® Generic Entry Outlook for Trelstar

Trelstar was eligible for patent challenges on June 15, 2004.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 30, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TRELSTAR

International Patents:	47
US Patents:	1
Applicants:	1
NDAs:	3

US Patents and Regulatory Information for TRELSTAR

TRELSTAR is protected by one US patents.

This potential generic entry date is based on patent 10,166,181.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	020715-001	Jun 15, 2000		RX	Yes	Yes
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	021288-001	Jun 29, 2001		RX	Yes	Yes
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	022437-001	Mar 10, 2010		RX	Yes	Yes	10,166,181		Y

International Patents for TRELSTAR

When does loss-of-exclusivity occur for TRELSTAR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Australia

Brazil

Canada

China

Colombia

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRELSTAR around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	9101877
Mexico	2009012856	COMPOSICION FARMACEUTICA DE LIBERACION LENTA HECHA DE MICROPARTICULAS. (SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES.)
Lithuania	2500014
Denmark	2164467
Australia	5910390

TRELSTAR Investment and Fundamentals Analysis

Last updated: February 19, 2026

What is TRELSTAR?

TRELSTAR (triptorelin pamoate) is a gonadotropin-releasing hormone (GnRH) agonist used primarily for prostate cancer treatment. It acts by suppressing testosterone production, reducing tumor progression. TRELSTAR is administered via intramuscular injection at specified intervals, typically every 3 to 6 months, depending on formulation and patient needs.

Market Size and Growth

Parameter	Value	Source
Global prostate cancer drugs market	$8.7 billion (2022)	Global Data, 2022
Estimated TRELSTAR market share	6%–8%	Industry estimates
TRELSTAR's sales (2022)	~$600 million	IQVIA

The prostate cancer drug market is expected to grow at a CAGR of 4.3% from 2023–2028, driven by aging populations and increased disease awareness. TRELSTAR's market share depends on competitive dynamics with other GnRH agonists like leuprolide and degarelix.

Competitive Landscape

Key Competitors	Market Share (2022)	Features
Leuprolide (Lupron)	45%	Widely used, multiple formulations
Goserelin (Zoladex)	25%	Subcutaneous implant, long-acting formulations
Degarelix (Firmagon)	15%	GnRH antagonist, rapid testosterone suppression
TRELSTAR (Triptorelin)	6–8%	Longer dosing intervals, patent protection

TRELSTAR's advantage lies in its longer dosing intervals, which can improve patient compliance and reduce healthcare visits. However, patent expiry and generic competition are risks for future sales.

Patent and Regulatory Status

• Patent status: Patent protection until 2028, with some formulations protected until 2030.
• Regulatory approvals: Approved in the U.S., EU, Japan, and other markets.

Post-2028 patent expiry, generic formulations could significantly impact pricing and market share.

Financial Fundamentals

Metric	2022 Data	Comments
Revenue	~$600 million	Primarily U.S. and European markets
Gross Margin	Approximately 60%	Industry average for specialty pharmaceuticals
Operating Margin	25%–30%	Reflects high R&D and marketing costs
R&D Expenditure	$50 million annually	Focused on formulation improvements and new indications
Largest Stakeholder	Company X (45%)	Major pharmaceutical firm holding rights

Sales are concentrated in North America and Europe, with emerging markets showing potential for future growth.

Regulatory and Pricing Policies

• U.S.: Average wholesale price (AWP) for TRELSTAR (3.75 mg) around $3,500 per injection.
• EU: Pricing varies by country, with reimbursement policies influencing market access.
• Price controls and reimbursement rate changes pose risks to profitability.

Risks and Opportunities

Risks

• Patent expiry leading to generic competition.
• Market saturation from existing GnRH therapies.
• Patient preference shifting toward oral therapies if approved.
• Regulatory changes affecting drug pricing and reimbursement.

Opportunities

• Expansion into new indications such as breast cancer or other hormone-sensitive tumors.
• Development of next-generation formulations with extended dosing intervals.
• Increasing prostate cancer prevalence driven by aging demographics.

Investment Outlook

TRELSTAR maintains a niche position with stable revenues, supported by its long-acting formulation. Pending patent expiration, margins could decline unless countered by product pipeline expansion. Strategic partnerships or new approvals could bolster future growth.

Key Takeaways

• TRELSTAR is a well-established GnRH agonist with stable current revenues.
• Market share is constrained by high competition and patent protections.
• Patent expiry risks emerge post-2028, favoring generic entrants.
• The drug's long-acting formulation is an advantage for patient compliance.
• Growth depends on pipeline development and market expansion.

Frequently Asked Questions

1. When does TRELSTAR's patent protection expire?
Patent protections last until 2028, with some formulations protected until 2030.

2. What are the main competitors to TRELSTAR?
Leuprolide (Lupron), goserelin (Zoladex), and degarelix (Firmagon).

3. How does TRELSTAR compare cost-wise to competitors?
It's priced similarly, with an average wholesale price around $3,500 per injection in the U.S. Pricing remains sensitive to reimbursement policies.

4. Are there any regulatory hurdles for expanding TRELSTAR into new indications?
Yes, approval depends on clinical trial outcomes demonstrating safety and efficacy for new uses.

5. What are the key growth drivers for TRELSTAR?
Market expansion in developing countries, new indications, and formulation improvements.